Fennec Pharmaceuticals : Corporate Presentation May 2026

Published: 2026-05-18 12:08:14 ET FENC

Published on 05/18/2026 at 12:08 pm EDT

Corporate Presentation

M ay 2026

W W W .F E N N E CP H AR M A.CO M

FEN-1321-v15

Fennec is changing the sound of cancer care

Transforming Cancer Care with PEDMARK®

The first and only FDA-approved therapy for cisplatin-induced ototoxicity (CIO)*:

Endorsed in NCCN treatment guidelines for preventing CIO in AYA** cancer

Protected Foundation for Long-term Value

Robust IP portfolio supporting durable differentiation and global expansion

Generic will not enter market in U.S. until September 1, 2033

Pediatric Use Marketing Authorization (10 yrs) in Europe

European partnership with Norgine

Japan registration preparation underway

Partnership with InPharmus to expand in GCC market

Rebuilt and Refocused for Execution

A renewed organization and leadership team driving sharper commercial and medical focus

6 quarters of consecutive revenue growth

*CIO,: Cisplatin Induced Ototoxicity **AYA: Adolescent & Young Adult 3

They rang the bell. But some couldn't hear it.

Survival should sound like something.

A voice you love, a laugh breaking through. That's the promise they fought for.

But an asterisk creeps in.

It quiets the victory for 60-90% of cancer survivors. A child's call, a ring of the bell-they fade.

Survival should echo loud, not sit in silence with a mark. Victory over cancer shouldn't come with a loss.

With PEDMARK®, more of their survival could be heard.

SURVIVAL SHOULD BE LOUD

Cisplatin: A Cornerstone of Modern Cancer Care -with a Caveat

If the price of curing a childhood cancer patient is permanent hearing loss, we haven't fully healed the child

> Dr. F, Pediatric Oncologist, Academic Institution

CONFIDENTIAL INFORMATION - For intended audiences only. Do not copy or distribute. MED-FEN-1672-v6 09/25

Cisplatin is an indispensable component of treatment

Overall survival rates

for some cancers treated with cisplatin can reach upwards of 87%1,2

Pediatric1

Germ Cell Tumors

Adolescents and Young Adults (AYA)1

Chattaraj A, et al. JCO Oncol Pract. 2023;19(5):278-283. 2. Gold JM, Raja A. Cisplatin. 2023 May 22. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. PMID: 31613475.

Despite its effectiveness, cisplatin causes irreversible hearing loss

60% to 90% of patients treated with cisplatin may develop hearing loss2-4

Cisplatin Induced Ototoxicity (CIO)

CIO permanent hearing loss estimates5:

40-80%

OF ADULTS

50-90%

OF CHILDREN

Common Clinical Presentation of Hearing Loss

High frequency (≥4 kHz) sensorineural hearing loss1,2

Bilateral (both ears)

Progressive

Irreversible

Can progress to include lower frequencies (<4 kHz)3

Can be accompanied by tinnitus3

Prolonged retention of platinum in the cochlear tissues may cause hearing loss progression after completion of therapy4

Hearing aids may be necessary in up to 40%; and cochlear implants in an additional percentage of children affected3

1. Waissbluth S et al. Int J Pediatr Otorhinolaryngol. 2018;111:174-179. 2. Paken J et al. J Toxicol. 2016;2016:1809394. 3. Langer T et al. Trends in Pharmacological Sciences. 2013;34:458-469. 4. Sprauten M. J. Clin Oncol. 2012;30:300-307. 5. Breglio AM et al. Nat Commun. 2017;8(1):1654. 7

Damage can start early-often within just one or two cycles

Ototoxicity is a cisplatin dose-limiting toxicity1 meaning that efficacy of chemotherapy could be compromised due to ototoxicity management

Effects can be seen as soon as the second or third dose of cisplatin

Significantly more platinum is retained in the cochleae for patients on cisplatin compared to untreated patients2

Survivors are at risk of hearing deterioration years after completion of therapy3

HE A R I N G T HR E S HO L D L E V E L I N DB

Audiogram indicates how loud a sound must be to hear it at a given frequency.

100

F R E Q U E N C Y I N K HZ

*Audiogram of 1 patient

0.125 0.25 0.5 1 1.5 2 3 4 6 8 10

Pre Post 1st block Post 2nd block Post 3rd block Post 4th block 1st follow up

1. Langer T et al. Trends in Pharmacological Sciences. 2013;34:458-469. 2. Breglio AM, et al. Nat Commun. 2017;8(1):1654. 3. Bertolini P et al, J Pediatric Hem Onc 2004;26:649-655. 8

The Unseen Burden

I didn't know there was the possibility of permanent hearing loss; the muffled and sometimes high-pitched, shrill reminder that something in me broke and won't be fixed.

> Katy M.,

Cancer Survivor & Audiologist

Tinnitus & hearing loss: the iceberg model

Auditory Component1:

Ringing in the ears1

Difficulty hearing1

Decreased sound tolerance1

Other components include: Communication issues1, avoidance of social settings1, difficulty concentrating1, chronic stress1, ongoing hearing loss monitoring1, frustration1

Pineault, D. The Bidirectional Association between Tinnitus & Mental Well-being: Clinical Implications for Audiologists. 2-25

Non-Auditory Component1:

Avoidance of social settings1

Isolation1

Chronic stress1

Hearing loss changes how patients live, learn, and connect

You just want the cancer to be over with. The hearing loss is a constant reminder of the worst two years of my life and a permanent mark that the cancer left on me.

> Patient with Cisplatin Induced Ototoxicity

Patients with hearing loss resulting from cancer treatment have a statistically significant worse quality of life

compared with peers who have no hearing loss1,3

Hearing loss impacts many aspects of life, such as speech and language skills,2 academic performance,2 social-emotional development,2 career potential3, and the ability to live independently3

Treatment-related hearing loss may cause considerable emotional stress for survivors, including depression,3 anxiety,1 low self-esteem,1 and embarrassment4

1. Rajput K, et al. Int J Pediatr Otorhinolaryngol. 2020;138:110401. 2. Clemens E, et al. Lancet Oncol. 2019;20(1):e29-e41. 3. Bass JK, et al. Pediatr Blood Cancer. 2016;63(7):1152-1162.

4. Khan A, et al. Cancer. 2020;126(8):1776-1783.

For decades, oncologists had no way to prevent CIO

Management through treatment modifications that could impact survival, or management of hearing loss when treatment has been completed:

Hearing Aids1

Speech Rehabilitation3

Personal Frequency Modulation

(FM Classroom Amplification)

Cochlear Implants1

1. Landier W. Cancer. 2016;122:1647-1658. 2. https://www.starkey.com/blog/2014/02/5-common-questions-about-hearing-aids accessed Feb 18th 2020. 3. Paken et al, Journal of Toxicology 2016, 1809394 | Image: https://pubs.asha.org/

Financial impact of severe to profound hearing loss can be considerable across a patient's lifespan1

$1M1

Lifetime cost of hearing loss can exceed USD

Lifetime cost for individuals with early onset of severe to profound hearing loss

Educational Costs

*Based on 2023 USD

Medical Costs

SPHL, severe to profound hearing loss

1. Cejas I et al. Laryngoscope. 2024;134(10):4358-4365.

No Proven Protection

- Until Now

This is the kind of innovation that reminds us that cancer care isn't just about survival. It's about living well after.

> Dr. P., Pediatric Oncologist, Academic Institution

PEDMARK® (sodium thiosulfate injection): Clinically proven to reduce the risk of hearing loss without compromising cancer treatment

≥1 month of age with localized, non-metastatic solid tumors

Proven protection. Established safety. Consistent benefit.

Rapid infusion time and clear benefit with

~50% reduction in hearing loss

Unique formulation and a differentiated excipient profile with mild-to-moderate and manageable side effect profile

Please see Important Safety Information at the end of this presentation Full Prescribing Information is available at https://www.PEDMARK.com

National guidelines affirm the importance of preventing hearing loss in AYA cancer patients with 2A recommendation

The Adolescent and Young Adult (AYA) oncology patient is defined as an individual aged 15-39 years of age at the time of initial cancer diagnosis

Guidelines recommend sodium thiosulfate (PEDMARK), the only FDA-approved treatment

to reduce the risk of CIO, backed by 2 clinical trials1-4

Recommended for the Adolescent and Young Adult (AYA) population by the NCCN Guidelines®*

The guidelines are clear. Now hear what's possible

These recommendations are not consistent with the FDA-approved indication. Always refer to the PEDMARK Prescribing Information and Instructions for Use.

NCCN CATEGORY 2A Recommended

NCCN Guidelines for AYA Oncology recommends sodium thiosulfate (PEDMARK) as a Category 2A preventative treatment option to reduce hearing loss associated with platinum-based chemotherapy in patients with localized non-metastatic tumors²

NCCN Guidelines define an adolescent and young adult (AYA) oncology patient as an individual between 15 and 39 years.

NCCN makes no warranties of any kind whatsoever regarding their content, use of application and disclaims any responsibility for their application or use in any way.

1. Landier W. Ototoxicity and cancer therapy. Cancer. 2016;122(11):1647-1658. 2. PEDMARK® (sodium thiosulfate injection) full Prescribing Information. Hoboken, NJ: Fennec Pharmaceuticals, Inc.; 2023. 3. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Adolescent and Young Adult (AYA) Oncology Version 1.2026. © National Comprehensive Cancer Network, Inc. 2025. All rights reserved. Accessed March 2026. 4. Hennegan K, Silber A, Dehipawala S, Chithran K, Lockhart D. Evaluating the burden of survival of platinum-induced hearing loss in pediatric solid tumor patients: a systematic

literature review. Poster presented at: ISPOR Annual Meeting 2020; May 18-20, 2020 (virtual). 16

In the pediatric population, the need for hearing protection extends across geographies

Annual Incidence of Pediatric Solid

Tumor Cases in Both

U.S. and EU Markets*

Top Three Tumor Types:

Neuroblastoma, CNS & Osteosarcoma

U.S. MARKET

2,157

Cisplatin-Treated Patients

PEDMARK® MARKET

EUROPEAN MARKET

1,250

Cisplatin-Treated Patients

PEDMARK® MARKET

*EU market defined by Norgine-licensed countries, including Europe (EU-5 plus BENELUX, Nordics, Portugal, Ireland, CH, Austria)

*Sources: Fennec and Norgine Data on File

Localized vs metastatic breakdown based on Qualitative Market Research Study Completed February 2018

90% of U.S.

pediatric cancer patients receive care at ~200 top centers nationwide

Institutions

~200 target pediatric hospital centers, including COG, NCI and NCCN institutions*

~90% of pediatric cancer patients treated in key centers

SEATTLE

MINNEAPOLIS

DETROIT

BOSTON

NYC

CHICAGO

PHILADELPHIA

RALEIGH

LOS ANGELES

DALLAS

NEW ORLEANS

HOUSTON

MIAMI

1. Children's Oncology Group (COG). Impact of COG's Research. Last accessed November 2025. 2. National Cancer Institute (NCI)-Designated Cancer Centers. Last Accessed November 2025. Forte G et al. American Society of Clinical Oncology National Census of Oncology Practices: Preliminary Report. JOP 9, 9-19(2013). Vol. 9, Number 1. DOI: 10.1200/JOP.2012.000826

*COG: Children's Oncology Group; NCI: National Cancer Institute; NCCN: National Comprehensive Cancer Network

In the adolescent and young adult population, solid tumors remain

a significant challenge in the U.S.

Annual Incidence of AYA Solid Tumor Cases in the U.S.*

U.S. MARKET

Cisplatin-Treated Patients with Non-Metastatic Solid Tumors PEDMARK® MARKET

Top Tumor Types Include:

Germ Cell, Testicular, Thyroid and Breast

Incidence data presented herein is derived from a comprehensive analysis of scientific literature, proprietary market research, and Fennec data on file.

Community Centers

Across the U.S.

Academic Centers

Across the U.S.

Academic Centers

AYA cancer care spans the nation-led by academic centers, delivered in community practices

Academic Institutions Play Critical Role in Establishing Treatment Landscape

72 NCI-designated academic centers with ~20% of patients

3,750 community centers with

~80% of patients

Clinical Cancer Centers

Scientific Leadership, Resources & Research

Comprehensive Cancer Centers

Leadership, Resources, Plus Added Depth of Research & Transdisciplinary Research Across Scientific Areas

Basic Laboratory Cancer Centers

Focus on Lab Research & Preclinical Research

1. Data on File. 2. ASCO National Census of Oncology Practices: Preliminary Report 2013. 3. ASCO 2025 Snapshot: The State of the Hematology and Medical Oncologist Workforce. 4. Ellis SD et al. J Rural Health. 2022 Sep;38(4):865-875. 5. National Cancer Institute. NCI-Designated Cancer Centers; last accessed Nov. 2025. https://www.cancer.gov/research/infrastructure/cancer-centers

Disclaimer

Fennec Pharmaceuticals Inc. published this content on May 18, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on May 18, 2026 at 16:07 UTC.